Clinical Trial

Super Selective Adrenal Artery Embolization for Primary Aldosteronism: a Prospective Cohort Study(SAAE-PA)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study was to evaluate the efficacy and safety of adrenal vein blood extraction for primary aldosteronism classification and adrenal artery embolization in the treatment of primary aldosteronism, to provide new evidence plan for the diagnosis and treatment of primary aldosteronism, and to promote the development of adrenal artery embolization as a new treatment for primary aldosteronism.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-15.
Trial Details
NCT Number NCT06513676
Lead Sponsor Xinjiang Medical University
Conditions Primary Aldosteronism, Super Selective Adrenal Arterial Embolization
Enrollment 500 participants
Start Date 2024-04-15
Primary Completion 2026-06-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-23